Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L) In the PETHEMA/GEM2012MENOS65 ...

The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

New tools for monitoring multiple myeloma were a key topic at the European Hematology Society Congress. Advances in drugs and combinations have revolutionized the landscape in multiple myeloma, thus ...

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an ...

When it comes to the laboratory workflow, researchers typically leverage the best attributes of multiple analytical instruments to evaluate complex cell-based assays. However, advanced flow cytometers ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

Flow cytometry is a way to look closely at the features of cells or particles. A sample of blood or tissue goes into a machine called a cytometer. In less than a minute, a computer can analyze ...

Please could you both introduce yourselves and give a brief outline of your roles at Cerba Research? ADB: My name is Ans De Beuckelaer. I have a Ph.D. in biotechnology from the University of Ghent. In ...